Y. Grosse, R. Baan, and K. Straif, A review of human carcinogens???Part A: pharmaceuticals, The Lancet Oncology, vol.10, issue.1, pp.13-17, 2009.
DOI : 10.1016/S1470-2045(08)70286-9

J. Collins, J. Blake, and P. Crosignani, Breast cancer risk with postmenopausal hormonal treatment, Human Reproduction Update, vol.11, issue.6, pp.545-560, 2005.
DOI : 10.1093/humupd/dmi028

N. Shah, J. Borenstein, and R. Dubois, Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis, Menopause, vol.12, issue.6, pp.668-678, 2005.
DOI : 10.1097/01.gme.0000184221.63459.e1

C. Greiser, E. Greiser, and M. Doren, Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials, Human Reproduction Update, vol.11, issue.6, pp.561-573, 2005.
DOI : 10.1093/humupd/dmi031

V. Beral, G. Reeves, D. Bull, and J. Green, Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy, JNCI Journal of the National Cancer Institute, vol.103, issue.4, pp.296-305, 2011.
DOI : 10.1093/jnci/djq527

R. Chlebowski, S. Hendrix, and R. Langer, Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women, JAMA, vol.289, issue.24, pp.3243-3253, 2003.
DOI : 10.1001/jama.289.24.3243

R. Chlebowski, J. Manson, and G. Anderson, Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study, JNCI Journal of the National Cancer Institute, vol.105, issue.8, pp.526-535, 2013.
DOI : 10.1093/jnci/djt043

J. Rossouw, G. Anderson, and R. Prentice, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, vol.288, issue.3, pp.321-333, 2002.

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-427, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

V. Ringa and A. Fournier, La diminution de l???utilisation du traitement hormonal de la m??nopause a-t-elle fait baisser l???incidence du cancer du sein en France (et ailleurs)???, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.5, pp.297-301, 2008.
DOI : 10.1016/j.respe.2008.07.085

K. Zbuk and S. Anand, Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries, Journal of Epidemiology and Community Health, vol.66, issue.1, pp.1-7, 2012.
DOI : 10.1136/jech.2008.083774

A. Fournier, S. Mesrine, M. Boutron-ruault, and F. Clavel-chapelon, Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?, Journal of Clinical Oncology, vol.27, issue.31, pp.5138-5143, 2009.
DOI : 10.1200/JCO.2008.21.6432
URL : https://hal.archives-ouvertes.fr/inserm-01319999

R. Prentice, J. Manson, and R. Langer, Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause, American Journal of Epidemiology, vol.170, issue.1, pp.12-23, 2009.
DOI : 10.1093/aje/kwp115
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733042

A. Fournier, F. Berrino, and F. Clavel-chapelon, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study, Breast Cancer Research and Treatment, vol.95, issue.1, pp.103-114, 2008.
DOI : 10.1007/s10549-007-9523-x
URL : https://hal.archives-ouvertes.fr/inserm-00201813

N. Allen, K. Tsilidis, and T. Key, Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition, American Journal of Epidemiology, vol.172, issue.12, pp.1394-1403, 2010.
DOI : 10.1093/aje/kwq300

M. Stefanick, G. Anderson, and K. Margolis, Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy, JAMA, vol.295, issue.14, pp.1647-1657, 2006.
DOI : 10.1001/jama.295.14.1647

C. Greiser, E. Greiser, and M. Doren, Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis, Human Reproduction Update, vol.13, issue.5, pp.453-463, 2007.
DOI : 10.1093/humupd/dmm012

C. Pearce, K. Chung, M. Pike, and A. Wu, Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin, Cancer, vol.83, issue.3, pp.531-539, 2009.
DOI : 10.1002/cncr.23956

H. Yang, W. Anderson, and P. Rosenberg, Ovarian Cancer Incidence Trends in Relation to Changing Patterns of Menopausal Hormone Therapy Use in the United States, Journal of Clinical Oncology, vol.31, issue.17, pp.2146-2151, 2013.
DOI : 10.1200/JCO.2012.45.5758

B. Zhou, Q. Sun, and R. Cong, Hormone replacement therapy and ovarian cancer risk: A meta-analysis, Gynecologic Oncology, vol.108, issue.3, pp.641-651, 2008.
DOI : 10.1016/j.ygyno.2007.12.003

V. Beral, D. Bull, J. Green, and G. Reeves, Ovarian cancer and hormone replacement therapy in the Million Women Study, The Lancet, vol.369, issue.9574, pp.1703-1710, 2007.
DOI : 10.1016/S0140-6736(07)60534-0

L. Morch, E. Lokkegaard, A. Andreasen, S. Kruger-kjaer, and O. Lidegaard, Hormone Therapy and Ovarian Cancer, JAMA, vol.302, issue.3, pp.298-305, 2009.
DOI : 10.1001/jama.2009.1052

F. Grodstein, P. Newcomb, and M. Stampfer, Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis, The American Journal of Medicine, vol.106, issue.5, pp.574-582, 1999.
DOI : 10.1016/S0002-9343(99)00063-7

K. Lin, W. Cheung, J. Lai, and E. Giovannucci, The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer, International Journal of Cancer, vol.50, issue.2, pp.419-430, 2012.
DOI : 10.1002/ijc.26026

R. Chlebowski, J. Wactawski-wende, and C. Ritenbaugh, Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women, New England Journal of Medicine, vol.350, issue.10, pp.991-1004, 2004.
DOI : 10.1056/NEJMoa032071

H. Ziel and W. Finkle, Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens, New England Journal of Medicine, vol.293, issue.23, pp.1167-1170, 1975.
DOI : 10.1056/NEJM197512042932303

D. Smith, R. Prentice, D. Thompson, and W. Herrmann, Association of Exogenous Estrogen and Endometrial Carcinoma, New England Journal of Medicine, vol.293, issue.23, pp.1164-1167, 1975.
DOI : 10.1056/NEJM197512042932302

S. Furness, H. Roberts, J. Marjoribanks, and A. Lethaby, Hormone therapy in postmenopausal women and risk of endometrial hyperplasia, Cochrane Database Syst Rev, vol.8, p.402, 2012.

R. Santen, D. Allred, and S. Ardoin, Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.7_supplement_1, pp.1-66, 2010.
DOI : 10.1210/jc.2009-2509

L. Brinton and A. Felix, Menopausal hormone therapy and risk of endometrial cancer, The Journal of Steroid Biochemistry and Molecular Biology, vol.142, 2013.
DOI : 10.1016/j.jsbmb.2013.05.001

A. Fournier, Should transdermal rather than oral estrogens be used in menopausal hormone therapy?: a review, Menopause International, vol.16, issue.1, pp.23-32, 2010.
DOI : 10.1258/mi.2010.010009
URL : https://hal.archives-ouvertes.fr/inserm-01320273